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International meeting: new diagnostic tests are urgently  
needed to treat patients with Chagas disease
Reunião internacional: novos testes diagnósticos são necessários urgentemente 
para tratar pacientes com doença de Chagas
Médecins Sans Frontières. Campaign for Access to Essential Medicines  
Rio de Janeiro, RJ, August 30-31, 2007
ABSTRACT
Trypanosoma cruzi infection is often not detected early on or actively diagnosed, partly because most infected individuals are either asymptomatic or 
oligosymptomatic. Moreover, in most places, neither blood banks nor healthcare units offer diagnostic confirmation or treatment access. By the time 
patients present clinical manifestations of advanced chronic Chagas disease, specific treatment with current drugs usually has limited effectiveness. 
Better-quality serological assays are urgently needed, especially rapid diagnostic tests for diagnosis patients in both acute and chronic phases, as well as 
for confirming that a parasitological cure has been achieved. Some new antigen combinations look promising and it is important to assess which ones 
are potentially the best, together with their requirements in terms of investigation and development. In August 2007, a group of specialized researchers 
and healthcare professionals met to discuss the state of Chagas infection diagnosis and to build a consensus for a plan of action to develop efficient, 
affordable, accessible and easy-to-use diagnostic tests for Chagas disease. This technical report presents the conclusions from that meeting.
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RESUMO
A infecção pelo Trypanosoma cruzi não é comumente detectada cedo ou diagnosticada ativamente, em parte porque a maioria dos infectados é 
assintomática ou oligossintomática e nem os bancos de sangue nem as unidades de saúde oferecem, na maioria dos lugares, nem a confirmação do 
diagnóstico nem o acesso ao tratamento. Habitualmente, quando os pacientes apresentam manifestações clínicas avançadas da doença crônica o 
tratamento específico com os medicamentos atuais tem efetividade limitada. São necessárias urgentemente provas sorológicas de melhor qualidade, 
e em especial provas diagnósticas rápidas, para diagnosticar pacientes na fase aguda e crônica, assim como para confirmar a cura parasitológica. 
Algumas novas combinações de antígenos são promissoras e é importante avaliar as potencialmente melhores, assim como as suas necessidades em 
nível de pesquisa e desenvolvimento. Em agosto 2007, um grupo de pesquisadores especializados e profissionais da área da saúde se reuniu para 
discutir a situação do diagnóstico da infecção chagásica e elaborar um consenso sobre um plano de ação em prol do desenvolvimento de testes 
diagnósticos eficientes, acessíveis e fáceis de usar. Este informe técnico apresenta as conclusões da reunião. 
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Trypanosoma cruzi infection is often not detected early on 
or actively diagnosed, partly because most infected individuals 
are either asymptomatic or oligosymptomatic. Moreover, in most 
places, neither blood banks nor healthcare units normally offer 
diagnostic confirmation or treatment access. By the time patients 
present clinical manifestations of advanced chronic Chagas 
disease, the specific treatment with current drugs usually has 
limited effectiveness. As a typical neglected illness, in most places 
Chagas disease has remained silent and silenced. International 
initiatives to combat Chagas disease have focused mostly on 
vector and transfusional control. Active screening and treatment 
of patients have rarely received the importance they deserve. 
The high infection/disease prevalence in countries like Bolivia 
highlights the need for a change in strategy.
Because of the situation regarding Chagas disease that has 
been described, Médecins Sans Frontières (MSF) has been 
working with patients suffering from Chagas disease since 1999 
(with more than 2,000 patients treated). Currently, MSF provides 
medical care to patients suffering from Chagas disease in two 
Bolivian projects, in Sucre and Cochabamba, where children 
and young adults are treated. In Bolivia and Guatemala, patients 
seen by MSF doctors in rural and peripheral urban areas have 
been diagnosed using a combination of serological tests. The 
recent introduction of rapid diagnostic tests (RDTs) has allowed 316
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MSF teams to assess patients through field diagnosis and active 
screening. However, the existing rapid tests have so far not fulfilled 
the diagnostic needs14. 
Better quality RDTs are urgently needed: tests that are proven 
to be effective and affordable for diagnosing patients in both 
the acute and chronic phases, as well as for confirming that 
a parasitological cure has been achieved. Some new antigen 
combinations look promising: it is important to discuss which of 
these are the best possible antigen combinations and what their 
requirements are, with regard to investigation and development. 
In August 2007, a group of specialized researchers and healthcare 
professionals met in Rio de Janeiro, Brazil, to discuss the state of 
Chagas infection diagnosis and to build a consensus for a plan of 
action to develop efficient, affordable, accessible and easy-to-use 
diagnostic tests for Chagas disease. This technical report presents 
the conclusions from that meeting.
SEROLOGICAL DIAGNOSIS OF TRYPANOSOMA CRUZI 
INFECTION
In the short initial acute phase, or in cases of reactivation 
due to immunosuppression, high parasitemia is observed and 
the diagnosis of Trypanosoma cruzi infection is based on 
direct parasitological tests. On the other hand, because of low 
parasitemia, in the chronic phase, the diagnosis is based on 
detection of antibodies, which are present in most patients in 
differing concentration titers, although their relationship with the 
degree of morbidity has not yet been established3 16. 
In the chronic phase, the serological diagnosis is usually 
performed using conventional commercial tests: indirect 
immunofluorescence assay (IFA), enzyme-linked immunosorbent 
assay (ELISA) and indirect hemagglutination assay (IHA). The 
main advantages of IFA are its high sensitivity, its qualitative results 
(describing the immunofluorescence pattern) and quantitative 
results (titers). The disadvantages of IFA are the need for an 
expensive fluorescence microscope, the dependence of its 
reliability on subjective reading and microscopist expertise, and 
its low processing speed. The main advantages of ELISA are its 
high sensitivity and specificity, depending on the antigen to be 
detected and the cutoff used, its ability to process large quantities 
of samples rapidly and its objective quantitative results. The 
disadvantages of ELISA are the need for a cold chain (samples 
at -20ºC and reagents at 2-8ºC), a skilled technician and rather 
expensive equipment and supplies. The main advantages of IHA 
are its relatively fast results (2h), lack of need for sophisticated 
equipment and its quantitative results (titers). The disadvantages 
of IHA are the lower sensitivity that it presents in relation to IFA 
and ELISA, the possibility of false positive results (especially in 
relation to poor storage, transportation conditions and even the 
intrinsic commercial kit performance), its low reproducibility, its 
variable reliability dependant on subjective reading, and the need 
for a cold chain for kit storage, as with IFA and ELISA1 10. 
According  to  World  Health  Organization  (WHO) 
recommendations, individual diagnoses have to be based on two 
conventional tests based on different principles and detecting 
different antigens. The conventional tests use a complex mixture 
of parasite antigens (IHA and ELISA) or the entire parasite itself 
(IFA). This increases the sensitivity, even when the antibody levels 
are low, but decreases the specificity, because of the presence of 
cross-reactions between Trypanosoma cruzi and Leishmania 
spp. Other examples of difficult diagnostic situations are the 
low levels of parasitemia involving Trypanosoma cruzi group 
I that are usually found in the Amazon region, along with other 
frequent coinfections and the presence of other autoimmune 
diseases. In case of doubtful results (values on the cutoff line or 
within the indeterminate zone) or discordant results, the tests 
can be repeated and a third test, preferably a confirmatory one, 
can also be used15. 
At the present moment, there are some candidates for 
confirmatory tests: radioimmunoprecipitation assays (RIPA), 
immunoblot assays using recombinant antigens and Western 
blot assays using trypomastigote excreted-secreted antigens 
(TESA-blot). 
RIPA, a highly sensitive and specific test with easily interpreted 
results, was developed two decades ago and has been suggested 
for use as a confirmatory test in the United States. Although RIPA 
has been used in more than 20 research projects as a confirmatory 
assay, its sensitivity and specificity have not been systematically 
validated. Moreover, its technical complexity and the fact that it is 
labor-intense and expensive and involves radioactivity would make 
its widespread use outside of research settings difficult4 5.
The INNO-LIA® Chagas assay is a type of commercially 
available immunoblot assay using seven recombinant and synthetic 
antigens: CRA, FRA, Tc-24, SAPA, MAP, TcD and Ag39, which are 
coated at separate locations onto a single nylon membrane strip. 
This physical separation of the different antigens prevents sterical 
hindrance during antibody binding, but this may be a problem if a 
mixture of the antigens is used in a single well of an ELISA plate. 
It presents high sensitivity and specificity, with no cross-reactions 
with leishmaniasis, but it is difficult to interpret the results and its 
high cost has limited its use7 8 11 12. 
Recently, a new combination of four recombinant antigens 
has been proposed (FP10, FP6, FP3 and TcF), also using an 
immunoblot principle. Each of these antigens is composed of 
several antigenically distinct regions and includes both repetitive 
and non-repetitive sequences. Each antigen is coated as a discrete 
line on a nitrocellulose strip. This assay presents high levels of 
sensitivity and specificity, and it is potentially suitable for use as a 
confirmatory test. It has already been evaluated commercially and 
the small number of bands facilitates interpretation through visual 
reading, without the need for laboratory instruments2.
The performance of the TESA-blot test for diagnosing 
Trypanosoma cruzi infection is related to the presence of shed 
acute-phase antigens (SAPA) in the acute phase and a band of 150-
160kDa in the TESA medium in the chronic phase. Differently from 
conventional tests detecting anti-Trypanosoma cruzi epimastigote 
antibodies, TESA-blot detects molecules that are only present 
in trypomastigote forms, the evolutionary form that is found in 
mammals (including humans) and is present in all Trypanosoma 317
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cruzi strains studied up to now (about 50). As TESA-blot presents 
high sensitivity and specificity, without cross-reactions with 
either visceral leishmaniasis or Trypanosoma rangeli, and it is 
apparently able to resolve more than 95% of serologically doubtful 
cases, it has been proposed as a confirmatory test13.
Responding to a new market need, rapid diagnostic tests 
(RDTs) have recently come onto the market, and some national 
Chagas disease programs, such as in Bolivia, have already included 
them in their national protocols for diagnosing Trypanosoma 
cruzi infection. However, the few RDTs available up to now do 
not fulfill the current field diagnostic needs. The main advantages 
of the RDTs identified so far have been: rapid processing (only a 
few minutes); no need for a cold chain, lab reagents, laboratory 
equipment or instruments; shelf life of 18 months at room 
temperature; no need for specialized laboratory technical skills; 
possibility of use on different types of samples (blood, serum or 
plasma); devices available in sealed pouches for individual use. 
On the other hand, the disadvantages of RDTs that have been 
identified include: their screening test category (not a diagnostic 
category – neither conventional nor recommended by WHO); 
some proportion of difficult-to-interpret results (weakly or very 
weakly result lines); non-quantitative results and consequent 
limitations on follow-up after treatment; few RDTs yet on the 
market; better specificity than sensitivity, which constrains the 
screening capacity; lack of performance assessment under 
different field conditions (temperature, humidity and altitude) 
with different Trypanosoma cruzi and human populations; and 
the high cost per device (without taking into account laboratory 
personnel, quality control and reagent storage)6 9.
CONCLUSIONS AND RECOMMENDATIONS CONCERNING 
CHRONIC CHAGAS DISEASE DIAGNOSIS
I. In Latin America, diagnoses using the conventional tests are 
made in big urban centers, but huge numbers of infected patients 
are in medium-sized towns and rural areas where there are neither 
any equipped laboratories nor any qualified human resources. The 
specific constraints in remote or poor areas are: the complexity 
of the protocols, which require at least two patient visits to the 
health center/laboratory; the technology needed (electricity and 
equipment); availability of qualified human resources; lack of or 
difficulty in access; delays in obtaining results, with consequent 
patient dropouts; and the high costs. On the other hand, when 
the conventional tests are used in rural or remote areas, it may be 
impossible to implement them or they may lose their published 
high sensitivity and specificity characteristics that were achieved 
under reference laboratory conditions.
II. The participants at the meeting agreed that the current 
approaches are insufficient to respond to the urgency of the 
global Chagas challenge and they call upon governments, 
intergovernmental agencies, researchers, diagnostic test and drug 
developers, non-governmental organizations and founders to take 
action in certain key areas:
1.  Accelerate development of high-quality rapid diagnostic tests 
for Chagas disease to reinforce the diagnostic capacity in 
poorly resourced settings, simplify diagnostic algorithms and 
facilitate access to treatment.
2.  Accelerate development of new generations of tests, with high 
sensitivity and specificity, for diagnosis of Trypanosoma cruzi 
infection, follow-up of patients after treatment and rapid cure 
verification.
3.  Accelerate discovery of new biomarkers using new 
technologies and increase sustainable funding for Chagas 
research and discovery activities and product development, 
as a matter of political prioritization.
4.  Commit to global Chagas research and discovery, sustained by 
strong political leadership to improve collaboration between 
scientists, test developers and care providers, in both rich and 
poor countries, for the global priority research agenda that is 
urgently needed for Chagas disease, and with a new model based 
on collaboration, sharing of data and coordination of efforts.
5.  Take new approaches to research and discovery, because the 
lack of development of Chagas tests comes from the failure 
of the existing mechanisms based on profit-driven research.
III. It is not possible to treat patients without diagnosis; serological 
diagnosis is an important entry point, and research and discovery 
may have a key role in specific remote areas or in specific areas 
where access to diagnosis does not exist. The desirable research 
and discovery characteristics should include the following:
1.  Rapidity in carrying out tests (without any need for equipment 
or instruments).
2.  Capacity for also performing tests on whole blood.
3.  Two-test strategy: firstly a test with high sensitivity (screening 
test) and secondly a test with high specificity (confirmatory 
test), using the same device if possible.
4.  Detection of specific acute-phase antibodies.
5.  Good performance in different Trypanosoma cruzi group 
regions. 
6.  Ideally, with quantifiable results for patient follow-up.
7.  Stability under field conditions (temperature up to 40ºC, 
humidity from 20 to 90%, altitude up to 4,000 meters), 
allowing storage for at least 18 months before use.
8.  Avoidance of blood sample shipment through using RDTs.
9.  Maintenance of reactivity lines for several months (until 
eventually checking).
10. Minimal user training required.
11. Validation using field samples and studies in endemic areas 
(multicenter studies).
12. Patient treatment made possible based on interpreting their 
test results.
13. Simplified algorithms, in relation to those used at present, 
making them more practical and field friendly.318
IV. In order to assess commercially produced RDT tests for whole 
blood, it is recommended that a three-stage comparative study 
should be conducted: a) collection of all the available information 
from the producers and from the scientific literature (foundation 
for good research projects and ethical committee procedures); 
b) testing on all kits with a serum panel in at least two different 
reference laboratories, one north of and the other south of 
the Amazon basin, in order to get comparative sensitivity and 
specificity information from them; c) testing on the selected kits 
with appropriate characteristics, in a prospective multicenter field 
study, with field groups working north and south of the Amazon 
basin and, preferably, also in the Amazon basin itself, where at the 
present moment outbreaks and isolated cases of oral and vector 
transmission are being detected.
V. Trypomastigote excreted-secreted antigens that were described in 
1996 and are free from patenting have so far been used by several 
scientific groups in different regions, using the ELISA and western blot 
formats. It is proposed to gather together all the available commercial 
and economic information generated by interested producers until 
now. It is also proposed that a complete meta-analysis should be 
performed on the protocols applied and the sensitivity and specificity 
results obtained, in order to identify strong and weak points relating to 
their commercialization. Finally, more studies are required to check 
on the possibility of using them for RDT support. 
VI. At the present moment, different names are given to similar 
Trypanosoma cruzi antigens. A nomenclature consensus is 
needed in order to facilitate worldwide information sharing.
VII. All commercial kits should inform their molecule compositions 
(Trypanosoma cruzi recombinant proteins or purified molecules) 
and sporadic changes during their lifetimes because of their important 
implications for day-to-day serological diagnosis and for comparative 
studies that are planned to assess commercially produced diagnostic 
kits. For this purpose and for promoting the development of new 
diagnostic kits, it is necessary to keep a permanently open channel 
of communication with worldwide producers.
VIII. Much has been done to advance the identification of 
Trypanosoma cruzi antigens. At the present moment, two 
important steps are identified: to work towards choosing the best 
possible combinations of existing antigens; and then to organize 
multicenter evaluations on these combinations, in order to expand 
their possible uses.
IX. The present challenges relating to cure verification include: the 
choice between serological and parasitological tests, with neither 
an easy nor a rapid answer; complexity of protocols; technology 
needed; technical challenges with present markers; lack of 
economic interest among producers; impossibility of detecting 
reinfections; time gaps and consequent patient dropouts; and 
unknown outcomes, leading to frustration among physicians and 
patients, thus jeopardizing new treatments. The present difficulty in 
cure verification is recognized especially after etiological treatment 
during the chronic phase. Consequently, there ought to be a test 
available to demonstrate within a short time that a cure has been 
achieved, or that there is a trend towards curing the disease.
X. The meeting participants welcome the resolution of the recent 
World Health Organization Consultation on International 
Biological Reference Preparations for Chagas Diagnostic 
Tests, in Geneva, on July 2-3, 2007, proposing the development of 
International Biological Reference Preparations for antibodies 
against Trypanosoma cruzi for use in the quality control of 
diagnostic tests, and enabling appropriate standardization of 
the tests at global level, as well as correct clinical diagnosis 
and blood screening.
XI. The meeting participants welcome the Global Network for 
Chagas disease Elimination (GNChE), which was launched at the 
recent World Health Organization meeting: Revisiting Chagas 
disease: from a Latin American health perspective to a global 
health perspective, in Geneva, on July 4-6, 2007, and they propose 
regular communication with the coordinators of the Technical 
Groups on Diagnostic test(s) for screening and diagnosis of 
Trypanosoma cruzi infections and on Prevention and control of 
congenital transmission and case management of congenital 
and non-congenital infections (Case-finding, diagnosis and 
treatment strategies at different health care levels that can be 
applied in endemic and non-endemic countries), in order to 
move forward in the best communicative and synergic way.
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